BofA analyst Allen Lutz lowered the firm’s price target on Hims & Hers to $20 from $24 and keeps a Buy rating on the shares. The firm believes Hims can deliver a mid-to-high teens revenue compound annual growth rate through 2027, even with a GLP-1 headwind in 2025, leading to $300M-plus of EBITDA in 2027, but lowers its multiple to reflect greater near-term risk to GLP-1 revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health call volume above normal and directionally bullish
- Unusually active option classes on open September 10th
- Hims & Hers files automatic mixed securities shelf
- Health apps temporarily profiting from copycat weight-loss drugs, FT says
- Viking Therapeutics selloff on Zepbound news an opportunity, says Truist